Follow The Filings

UTHR United Therapeutics Corporation

Health Care, filed as UNITED THERAPEUTICS CORP (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 2 Owners
  • Max 14.3%
  • $71M
  • 1 reduce 1 exit 1 small

In 2026 Q2 Michael Krensavage trimmed United Therapeutics, and Mairs & Power sold out.

Who owns this now

Largest portfolio weights among holders, up to 14.3% (Michael Krensavage, Krensavage Asset Management). Not free-float ownership.

  1. Michael Krensavage Reduce 14.3%
  2. Palo Alto Investors Reduce 4.7%

Who owns UTHR

Sorted by value, long equity only, as of 2026 Q2.

History
Michael Krensavage, Krensavage Asset Management 14.3%, was 19.5% Reduce −17.8% 69,282 $38M History
Palo Alto Investors 4.7%, was 5.7% Small trim −0.4% 62,587 $34M History
Mairs & Power exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 350 $208K History

2 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by UTHR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All UTHR insider trades
  • $864K bought by 1 insider
  • $8.8M sold by 5 insiders outside a trading plan
  • $1.4B sold by 8 insiders under 10b5-1 plans
  1. Martine A Rothblatt CEO
    Planned sale
    $5.7M 9,500 shares at $594.78 2.8% of stake
    Traded Oct 29 Filed Oct 30
    ↗
  2. Martine A Rothblatt CEO
    Planned sale
    $5.6M 9,500 shares at $585.49 2.8% of stake
    Traded Oct 28 Filed Oct 29
    ↗
  3. Martine A Rothblatt CEO
    Planned sale
    $5.6M 9,500 shares at $587.73 2.8% of stake
    Traded Oct 27 Filed Oct 28
    ↗
  4. Martine A Rothblatt CEO
    Planned sale
    $5.6M 9,500 shares at $588.64 2.8% of stake
    Traded Oct 26 Filed Oct 27
    ↗
  5. Martine A Rothblatt CEO
    Planned sale
    $5.5M 9,500 shares at $582.76 2.8% of stake
    Traded Oct 23 Filed Oct 26
    ↗
  6. Martine A Rothblatt CEO
    Planned sale
    $5.5M 9,500 shares at $583.38 2.8% of stake
    Traded Oct 22 Filed Oct 23
    ↗
  7. Martine A Rothblatt CEO
    Planned sale
    $5.3M 9,500 shares at $560.07 2.8% of stake
    Traded Oct 21 Filed Oct 22
    ↗
  8. Martine A Rothblatt CEO
    Planned sale
    $5.3M 9,500 shares at $553.87 2.8% of stake
    Traded Oct 20 Filed Oct 21
    ↗
  9. Martine A Rothblatt CEO
    Planned sale
    $5.2M 9,500 shares at $543.32 2.8% of stake
    Traded Oct 19 Filed Oct 20
    ↗
  10. Martine A Rothblatt CEO
    Planned sale
    $5.1M 9,500 shares at $534.66 2.8% of stake
    Traded Oct 16 Filed Oct 19
    ↗
  11. Paul A Mahon EVP & General Counsel
    Planned sale
    $4.5M 8,300 shares at $544.30 16% of stake
    Traded Oct 15 Filed Oct 16
    ↗
  12. Martine A Rothblatt CEO
    Planned sale
    $5.2M 9,500 shares at $546.65 2.8% of stake
    Traded Oct 15 Filed Oct 16
    ↗
  13. Martine A Rothblatt CEO
    Planned sale
    $5.1M 9,500 shares at $539.99 2.8% of stake
    Traded Oct 14 Filed Oct 15
    ↗
  14. Martine A Rothblatt CEO
    Planned sale
    $5.2M 9,500 shares at $545.52 2.8% of stake
    Traded Oct 13 Filed Oct 14
    ↗
  15. Martine A Rothblatt CEO
    Planned sale
    $5.2M 9,500 shares at $550.70 2.8% of stake
    Traded Oct 12 Filed Oct 13
    ↗

Also filed in the last 12 months, not counted as buying or selling: 335 option exercises, 8 share withholdings for taxes, and 4 gifts.

Congress

1 member of Congress traded UTHR in the last three years: 2 buys and 2 sales.

All Congress trades
  1. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Oct 31, 2025 filed Nov 21, 2025
  2. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Oct 30, 2025 filed Nov 21, 2025
  3. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Oct 30, 2025 filed Nov 21, 2025
  4. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Jun 11, 2025 filed Aug 13, 2025

SEC filings

Recent issuer filings from EDGAR, 2 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.33B $2.88B $3.18B
Gross profit $2.07B $2.57B $2.8B
Gross margin * 88.9% 89.2% 87.9%
Net income $0.985B $1.2B $1.33B
Net margin * 42.3% 41.5% 41.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $3.55B $3.87B $3.7B
Total non-current assets * $3.62B $3.49B $4.18B
Total assets $7.17B $7.36B $7.88B
Total current liabilities $804.4M $738.1M $560.6M
Total non-current liabilities * $377.8M $181.9M $223.2M
Total equity $5.98B $6.44B $7.1B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $0.978B $1.33B $1.56B
Cash from investing -$719.6M $417.2M -$551.3M
Cash from financing -$0.012B -$1.25B -$1.15B
Net change in cash $246.5M $489.5M -$140.1M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.